Scots man 'spent £400 a month on takeaways' before starting Mounjaro
A Scots man has revealed that he was spending around £400 on takeaways every month before going on Mounjaro.
Michael Monaghan, 40, had to shield during the pandemic and saw his weight go up. After gaining over three stone, and feeling 'everything else was failing', he made the decision to go on Mounjaro, reports Edinburgh Live.
The medication, which was created to treat diabetes, works by activating receptors to increase hormones in the body, producing more insulin when needed. It also reduces the amount of sugar produced by the liver and slows down food digestion.
After starting Mounjaro, Michael has seen hundreds of supportive messages on his YouTube channel where he's been posting videos of his journey. After booking a trip to Florida, he's set his goal of reaching 18 stone by the time he goes - having dropped two stone since starting Mounjaro four weeks ago.
Michael said: "The deciding factor was health. I was shielding during Covid and I gained a lot of weight.
"I think it was three and a half stone I gained. Then I kept putting on weight because I kept eating. What can I say, I enjoy food. And I basically just decided to start Mounjaro because everything else failed. I was waiting for weight management for a year and a half on the NHS, I couldn't believe it.
"England have started doing Mounjaro on the NHS but it's not up here yet, they haven't decided how that's going to happen. So I decided to pay for it privately out of my own pocket, I was spending £400 a month on takeaways - Just Eat, Uber Eats, whatever.
"If I take that money and put it into the jag, which is about £140 a month, I'm actually saving money. So that really changed my mindset."
While he's not a big fan of needles, Michael decided it was worth it. Knowing it was time, he felt he needed something to look forward to - which is where the Florida trip came in.
He continued: "I was curious about it, and I'd heard about the success people had, but I don't really like injecting myself. After looking into it, I just decided I have to do this.
"I have to try something, and I need something to look forward to. We booked a trip to Florida, so I've got a goal of 18 stone by the time we go.
"I'm a big Disney fan, I'm an annual pass holder for Paris. I love the rides, and if I don't lose weight then I won't be able to do them all - it's a target.
"I've got asthma and sleep apnea, and I've been told if I lose a bit of weight I might be able to get rid of that. It was getting uncomfortable, and this was the time to make a change and that's exactly what we've done."
Michael has received incredible support on his YouTube channel, with hundreds of comments that have motivated him on his journey. With the backing of his followers, he feels he 'can't stop now. '
He added: "Everybody has been so supportive, not one bad comment. I've had emails from people talking about their experiences on the same journey.
"It's really motivating for me, makes me feel like I can't give up. People understand that it's not just a case of going on a diet, it's about willpower."
While he had a rough start on Mounjaro, Michael feels he's had 'no side effects' since then. Admitting he does 'miss some foods', he's noticed his weight drop since he started.
He told us: "This medicine takes away my cravings, and I know it's working. The first three days were bad, I had to take some time off work as I couldn't get out of bed.
"I had cramps and a lot of pain, but it just went away and I haven't had any side effects since. I've come down from 22 stone and four pounds to 20 stone and 13 pounds.
"I'm still eating, drinking lots of water and I've cut out all sweets, chocolate, and stuff. I do miss some food, I was thinking about the new McDonald's burger the other day.
"When I lose enough weight, I could probably eat it. But before, I was eating two McDonald's a day on a daily basis and then home for sweets and crisps before late-night snacking.
"That's why I was gaining weight every year. But now, I don't feel as hungry, I'm not craving things. My face is starting to change, my body is starting to change and I'm more active and I've definitely got more energy. The change has been amazing.
"My portion sizes are about half of what they used to be. I'm going up from 2.5mg to 5mg dosage soon, so we'll see how that goes. I'm still eating what I'm eating, having the food I like, but everything is cut in half. I've stopped late night eating as well.
"I'm so motivated now, though, because I've noticed changes in myself, and I've got all these people from the YouTube channel behind me."
NHS Lothian is currently 'developing pathways' before a phased rollout of drugs, including Saxenda, Wegovy and Mounjaro.
They added: "NHS Lothian have a short life working group currently developing the pathway and once agreed we can start a phased roll out. We are aware of recent news of the roll out of weight loss medication prescribing in GP practices. Please note this applies to NHS England only.
"NHS Lothian is considering a phased roll out of these medicines for weight management in line with Scottish Government guidance. We are actively developing clinical pathways to ensure safe prescribing and monitoring. Updates will be shared once these clinical pathways have been agreed in NHS Lothian."
Join the Daily Record WhatsApp community!
Get the latest news sent straight to your messages by joining our WhatsApp community today.
You'll receive daily updates on breaking news as well as the top headlines across Scotland.
No one will be able to see who is signed up and no one can send messages except the Daily Record team.
All you have to do is click here if you're on mobile, select 'Join Community' and you're in!
If you're on a desktop, simply scan the QR code above with your phone and click 'Join Community'.
We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don't like our community, you can check out any time you like.
To leave our community click on the name at the top of your screen and choose 'exit group'.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South Wales Guardian
32 minutes ago
- South Wales Guardian
‘Groundbreaking' drug could slow down progression of type 1 diabetes
Teplizumab, which is already approved in the US, trains the immune system to stop attacking pancreatic cells, delaying the need for insulin by an average of three years. With type 1 diabetes, the immune system attacks insulin-producing cells in the pancreas, meaning blood sugar levels are no longer regulated by the body. If blood sugar is too high or low, it can cause serious health problems and even death. People with type 1 therefore need daily insulin. Dentist and mother-of-two, Hannah Robinson, from Devon, is the first adult in the UK to try the drug in the hope it can delay the condition. She is having treatment at the Royal Devon University Healthcare NHS Foundation Trust after discovering during pregnancy she was in the early stages of developing type 1. A handful of people are being given the medicine on a case-by-case basis while it is reviewed for wider use on the NHS. The 36-year-old said: 'For me, this new drug offers more freedom and the chance to focus on my health before I have to start thinking differently and managing life as somebody needing daily insulin. 'This isn't just about what I eat or monitoring my glucose, it is also about having more control and not feeling defined by my condition. 'This treatment could potentially pave the way for a future cure for type 1 diabetes, which is incredible. I feel very lucky to be part of this.' The new drug teplizumab must be given at the earliest stage of the disease to be effective. Dr Nick Thomas, diabetes consultant and academic clinical lecturer at the University of Exeter, said: 'This new treatment represents a really exciting shift in how we manage type 1 diabetes. 'For the first time ever, we will be able to provide targeted treatment early enough in the process to alter the underlying immune process, aiming to slow down how quickly people need insulin. 'Approximately half of all type 1 diabetes cases develop in adulthood, and Hannah will be the first adult in the UK to receive this treatment. 'My hope is that in the future, we may be able to stop people with early type 1 diabetes from needing insulin at all.' Experts at the Royal Devon and the University of Exeter are using genetics and other testing to spot people at high risk of developing type 1 diabetes. The hope is more people could be offered the drug to delay type 1. Dr Lucy Chambers, head of research impact and communications at Diabetes UK, said: 'For people in the early stages of type 1 diabetes, teplizumab offers a groundbreaking opportunity to buy them precious extra years insulin-free. 'Right now, it's only available in research settings – and while the excitement is real, urgent work is still needed to ensure it reaches everyone who could benefit. 'That means securing a UK licence for teplizumab, establishing national screening programmes to identify people with early-stage type 1 diabetes before symptoms appear, and preparing the NHS to deliver this treatment at scale. 'Diabetes UK is proud to be at the forefront of these efforts – funding pioneering research and working closely with the NHS towards a future where immunotherapies become the first-line treatment for tackling the autoimmune attack at the root of type 1 diabetes.' Professor Richard Oram, consultant physician at the Royal Devon and professor at the University of Exeter, said: 'Excitingly, teplizumab is the first drug with the potential to delay type 1 diabetes, but needs to be given before clinical diagnosis due to high blood glucose. 'It is really important to find new and improved approaches for identifying individuals at elevated risk.'
South Wales Guardian
32 minutes ago
- South Wales Guardian
Medicine shortages put patients at risk, MPs and peers warn
A new report from the All-Party Parliamentary Group (APPG) on pharmacy called for urgent action to ensure shortages do not become the 'new normal'. It also highlights the impact that shortages are having on patients with the likes of ADHD (attention deficit hyperactivity disorder), menopause and diabetes. Writing in the report, Steve Race, chairman of the APPG on pharmacy, said many MPs 'have received a growing volume of correspondence from constituents who are understandably anxious about the availability of their medicines'. 'Whether it is a parent unable to access antibiotics for a sick child, an elderly patient facing delays in obtaining life-sustaining medication, or a pharmacist overwhelmed by the need to source alternatives, the human impact is both visible and deeply troubling,' he wrote. The report said that while medicine shortages are 'not a new phenomenon', they have 'become increasingly severe, persistent, and disruptive' in recent years – leading to consequences for patients, staff and the wider health service. Mr Race said: 'Medicines shortages have moved from isolated incidents to a chronic structural challenge for both the NHS and pharmacy sector. 'As Government continues to recognise and invest in the expanded clinical role of community pharmacy, we must ensure the medicines supply chain underpinning that care is equally robust, resilient and patient-focused. 'Pharmacy is central to NHS recovery and transformation, but frontline teams cannot safely expand clinical services while daily supply disruptions continue to impact the health of patients.' The findings also highlight how shortages severely impact patients with conditions like ADHD, menopause and diabetes. More than nine in 10 pharmacists, GPs and prescribers told an APPG survey ADHD medicines had been affected by shortages. Around three quarters (76%) said HRT and diabetes drugs had been affected, while 44% said antibiotics. One patient with ADHD told the inquiry they had been self-medicating with cannabis due to an ongoing shortage of methylphenidate. The report said: 'These shortages are having a significant impact on patients' ability to access treatments and in some cases are having serious impact on patients' health and well-being.' Mr Race added: 'Medicines security must be treated as a core component of NHS planning, alongside funding, workforce and digital infrastructure. 'Failure to act risks further undermining patient care and destabilising a community pharmacy sector that millions depend upon.' The APPG has laid out a number of recommendations, which includes a number of measures to better support patients. People impacted by shortages, particularly those with chronic conditions, struggle to find information on out of stock drugs, leading to 'frustration, dangerous delays in care, and unnecessary anxiety and harm', it said. It also welcomed work being carried out by the Department of Health and Social Care to potentially change pharmacist prescribing protocols to allow pharmacists to make dose and formulation changes during shortages. Elsewhere, the inquiry found more than eight in 10 pharmacists face daily shortages, with many spending hours every day finding alternative treatment and communicating with distressed patients. One told the APPG they are 'constantly firefighting'. Reacting to the report, Henry Gregg, chief executive of the National Pharmacy Association (NPA), said: 'Pharmacy teams are under enormous pressure but are forced to spend hours hunting down stock for distressed and frustrated patients. 'It is particularly frustrating for pharmacists to be unable to meet a clear need when they have a perfectly safe and effective solution in their pharmacy already. 'MPs are right that it is madness to send someone back to their GP to get a prescription changed, and it risks a patient either delaying taking vital medication or forgoing it altogether, which poses a clear risk to patient safety. 'As the APPG says, the Government must allow pharmacists – who are highly trained health care practitioners – to use their professional judgment to supply an appropriate alternative medication when the prescribed version is unavailable.' A Department of Health and Social Care spokesperson said: 'This government inherited ongoing global supply problems, but we have robust measures in place to mitigate disruption for patients. 'We are working to build the resilience of medicine supply chains and prevent future disruption as we get the NHS back on its feet. 'We have recently agreed an extra £617 million of funding over two years with Community Pharmacy England to support the sector and provide patients with more services closer to home as part of our 10 Year Health Plan.'
North Wales Chronicle
40 minutes ago
- North Wales Chronicle
Medicine shortages put patients at risk, MPs and peers warn
A new report from the All-Party Parliamentary Group (APPG) on pharmacy called for urgent action to ensure shortages do not become the 'new normal'. It also highlights the impact that shortages are having on patients with the likes of ADHD (attention deficit hyperactivity disorder), menopause and diabetes. Writing in the report, Steve Race, chairman of the APPG on pharmacy, said many MPs 'have received a growing volume of correspondence from constituents who are understandably anxious about the availability of their medicines'. 'Whether it is a parent unable to access antibiotics for a sick child, an elderly patient facing delays in obtaining life-sustaining medication, or a pharmacist overwhelmed by the need to source alternatives, the human impact is both visible and deeply troubling,' he wrote. The report said that while medicine shortages are 'not a new phenomenon', they have 'become increasingly severe, persistent, and disruptive' in recent years – leading to consequences for patients, staff and the wider health service. Mr Race said: 'Medicines shortages have moved from isolated incidents to a chronic structural challenge for both the NHS and pharmacy sector. 'As Government continues to recognise and invest in the expanded clinical role of community pharmacy, we must ensure the medicines supply chain underpinning that care is equally robust, resilient and patient-focused. 'Pharmacy is central to NHS recovery and transformation, but frontline teams cannot safely expand clinical services while daily supply disruptions continue to impact the health of patients.' The findings also highlight how shortages severely impact patients with conditions like ADHD, menopause and diabetes. More than nine in 10 pharmacists, GPs and prescribers told an APPG survey ADHD medicines had been affected by shortages. Around three quarters (76%) said HRT and diabetes drugs had been affected, while 44% said antibiotics. One patient with ADHD told the inquiry they had been self-medicating with cannabis due to an ongoing shortage of methylphenidate. The report said: 'These shortages are having a significant impact on patients' ability to access treatments and in some cases are having serious impact on patients' health and well-being.' Mr Race added: 'Medicines security must be treated as a core component of NHS planning, alongside funding, workforce and digital infrastructure. 'Failure to act risks further undermining patient care and destabilising a community pharmacy sector that millions depend upon.' The APPG has laid out a number of recommendations, which includes a number of measures to better support patients. People impacted by shortages, particularly those with chronic conditions, struggle to find information on out of stock drugs, leading to 'frustration, dangerous delays in care, and unnecessary anxiety and harm', it said. It also welcomed work being carried out by the Department of Health and Social Care to potentially change pharmacist prescribing protocols to allow pharmacists to make dose and formulation changes during shortages. Elsewhere, the inquiry found more than eight in 10 pharmacists face daily shortages, with many spending hours every day finding alternative treatment and communicating with distressed patients. One told the APPG they are 'constantly firefighting'. Reacting to the report, Henry Gregg, chief executive of the National Pharmacy Association (NPA), said: 'Pharmacy teams are under enormous pressure but are forced to spend hours hunting down stock for distressed and frustrated patients. 'It is particularly frustrating for pharmacists to be unable to meet a clear need when they have a perfectly safe and effective solution in their pharmacy already. 'MPs are right that it is madness to send someone back to their GP to get a prescription changed, and it risks a patient either delaying taking vital medication or forgoing it altogether, which poses a clear risk to patient safety. 'As the APPG says, the Government must allow pharmacists – who are highly trained health care practitioners – to use their professional judgment to supply an appropriate alternative medication when the prescribed version is unavailable.' A Department of Health and Social Care spokesperson said: 'This government inherited ongoing global supply problems, but we have robust measures in place to mitigate disruption for patients. 'We are working to build the resilience of medicine supply chains and prevent future disruption as we get the NHS back on its feet. 'We have recently agreed an extra £617 million of funding over two years with Community Pharmacy England to support the sector and provide patients with more services closer to home as part of our 10 Year Health Plan.'
